Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript
11:16pm, Wednesday, 29'th Oct 2025
AtriCure, Inc. ( ATRC ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Pa
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings
06:31pm, Wednesday, 29'th Oct 2025
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics comp
AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates
06:11pm, Wednesday, 29'th Oct 2025
AtriCure (ATRC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago.
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
04:01pm, Wednesday, 29'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
08:00am, Tuesday, 28'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in Upcoming Investor Conferences
08:00am, Monday, 27'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Announce Third Quarter 2025 Financial Results
08:00am, Wednesday, 08'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
08:00am, Wednesday, 20'th Aug 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure (ATRC) Q2 Revenue Jumps 17%
03:19pm, Wednesday, 30'th Jul 2025
AtriCure (ATRC) Q2 Revenue Jumps 17%
AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript
07:14pm, Tuesday, 29'th Jul 2025
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
06:31pm, Tuesday, 29'th Jul 2025
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 29'th Jul 2025
AtriCure (ATRC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.17 per share a year ago.
AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025
04:01pm, Tuesday, 29'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference
08:00am, Monday, 28'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
08:00am, Tuesday, 15'th Jul 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain
